Author: digi

Bioanalytical Methods and Assay Development for Microdose Studies

May 15, 2025

Bioanalytical Methods and Assay Development for Microdose Studies Bioanalytical Techniques and Assay Development for Phase 0 Microdosing Trials Why Bioanalysis is Crucial in Microdose Studies In Phase 0 trials, drug doses are so small that plasma concentrations are often in the picogram to nanogram range. This means standard analytical methods may not be sensitive enough…

Preclinical Studies

Patient Recruitment and Retention in Clinical Trials: Strategies for Successful Enrollment and Long-Term Engagement

May 15, 2025

digi

Patient Recruitment and Retention in Clinical Trials: Strategies for Successful Enrollment and Long-Term Engagement Essential Strategies for Enhancing Patient Recruitment and Retention in Clinical Trials Patient recruitment and retention are among the most critical—and most challenging—aspects of clinical trial success. Timely enrollment and sustained participant engagement directly impact study timelines, data quality, regulatory approval, and…

Patient Recruitment and Retention

Advanced Therapy Medicinal Products (ATMPs) Regulation in the EU: An EMA Overview

May 15, 2025

digi

Advanced Therapy Medicinal Products (ATMPs) Regulation in the EU: An EMA Overview Understanding EMA Regulation of Advanced Therapy Medicinal Products (ATMPs) in the EU Advanced Therapy Medicinal Products (ATMPs) represent one of the most innovative and complex frontiers in modern medicine. Comprising gene therapies, somatic cell therapies, and tissue-engineered products, ATMPs hold the potential to…

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

Understanding FDA Risk Evaluation and Mitigation Strategies (REMS)

May 15, 2025

digi

Understanding FDA Risk Evaluation and Mitigation Strategies (REMS) A Comprehensive Guide to FDA’s Risk Evaluation and Mitigation Strategies (REMS) The U.S. Food and Drug Administration (FDA) has established the Risk Evaluation and Mitigation Strategies (REMS) framework to ensure that the benefits of certain medications outweigh their risks. REMS programs are crucial post-marketing tools used to…

Regulatory Guidelines, U.S. FDA Regulations

Step-by-Step Guide to Regulatory Submissions for Phase 0 Trials

May 15, 2025September 6, 2025

digi

Step-by-Step Guide to Regulatory Submissions for Phase 0 Trials Step-by-Step Guide to Regulatory Submissions for Phase 0 Clinical Trials Introduction: Regulatory Oversight in Phase 0 Trials Phase 0 trials, although short and low-risk, are still governed by regulatory frameworks. Before starting human studies, sponsors must obtain authorization from national health authorities. This ensures that human…

Phase 0 (Microdosing Studies)

Direct-to-Patient Drug Delivery in Clinical Trials: Enhancing Access and Convenience

May 15, 2025

digi

Direct-to-Patient Drug Delivery in Clinical Trials: Enhancing Access and Convenience Bringing Clinical Trials Home: Direct-to-Patient Drug Delivery for Modern Research Direct-to-Patient (DTP) drug delivery has become a pivotal innovation in decentralized and hybrid clinical trials, enabling investigational products (IP) to reach participants directly at their homes. By minimizing site visits and enhancing patient convenience, DTP…

Decentralized Clinical Trials (DCTs), Direct-to-Patient Drug Delivery

Compensation Rules for Clinical Trial Injury under CDSCO: A Detailed Guide

May 15, 2025

digi

Compensation Rules for Clinical Trial Injury under CDSCO: A Detailed Guide Understanding CDSCO’s Compensation Rules for Clinical Trial Injuries in India India’s clinical research environment has evolved with an emphasis on ethical conduct and subject safety. One significant development was the implementation of compensation rules for clinical trial-related injuries under the Central Drugs Standard Control…

CDSCO (India) Guidelines, Regulatory Guidelines

Ethics and Safety in Phase 0 Trials: What You Need to Know

May 15, 2025September 6, 2025

digi

Ethics and Safety in Phase 0 Trials: What You Need to Know Ethics and Safety in Phase 0 Trials: What Every Researcher Should Know Introduction: Ethics at the Heart of Human Research Even though Phase 0 trials involve microdoses and no therapeutic intent, they are still clinical trials involving human participants. This means they must…

Phase 0 (Microdosing Studies), Preclinical Studies

EMA Risk Management Plans (RMPs): A Guide to EU Pharmacovigilance Compliance

May 14, 2025

digi

EMA Risk Management Plans (RMPs): A Guide to EU Pharmacovigilance Compliance Comprehensive Overview of EMA Risk Management Plans (RMPs) in Pharmacovigilance Risk Management Plans (RMPs) are a fundamental requirement in the European Union’s pharmacovigilance landscape. Mandated by the European Medicines Agency (EMA), RMPs ensure that pharmaceutical companies proactively identify, characterize, and minimize risks associated with…

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

Post-Marketing Requirements Under FDA Authority: A Comprehensive Guide

May 14, 2025

digi

Post-Marketing Requirements Under FDA Authority: A Comprehensive Guide Understanding FDA Post-Marketing Requirements: Obligations Beyond Drug Approval Receiving U.S. FDA approval for a pharmaceutical product marks a significant milestone. However, this is not the end of regulatory oversight. Post-marketing requirements (PMRs) under the U.S. Food and Drug Administration (FDA) ensure continued safety, efficacy, and quality of…

Regulatory Guidelines, U.S. FDA Regulations